Elite Pharmaceuticals
Logotype for Elite Pharmaceuticals Inc

Elite Pharmaceuticals (ELTP) investor relations material

Elite Pharmaceuticals Q2 2027 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Elite Pharmaceuticals Inc
Q2 2027 earnings summary13 Nov, 2026

Executive summary

  • Q2 FY2027 revenue rose 10.4% YoY to $40.1M; operating income increased 21% to $9.9M and net income attributable to common shareholders was $17.3M.

  • H1 revenue fell 5% to $72.4M, while net income rose to $23.2M from $7.8M, aided by a $9.8M non-cash warrant fair-value gain.

  • H1 gross margin fell to 41% from 54% amid lower net prices and competition; priorities include pipeline and facility expansion and a Nasdaq listing targeted for March 2027.

Financial highlights

  • Q2 revenue was $40.1M versus $36.3M; gross profit rose to $16.0M from $14.1M, and operating income increased to $9.9M from $8.2M.

  • H1 gross profit decreased to $29.5M from $41.3M and operating income was $17.5M versus $29.9M; income before tax increased to $27.5M from $15.1M.

  • H1 R&D expense increased 35% to $1.9M; operating cash flow was $7.0M versus $19.9M, with prior-year cash flow benefiting from stronger Lisdex margins before market correction.

  • H1 investing cash outflow was $1.5M, primarily for property and equipment; financing cash outflow was $0.4M, primarily finance-lease principal.

Outlook and guidance

  • Management expects an approvable status for the filed anticoagulant in 2027, with launch targeted for 2028; its FDA GDUFA date is March 2027.

  • A second anticoagulant is in advanced development, with a bioequivalence study expected in H1 2027 and approval anticipated in 2028, subject to expectations being met.

  • At least one type 2 diabetes bioequivalence study is planned for H1 2027; the diabetes pipeline grew from three formulations to four.

  • An anticonvulsant ANDA filing is targeted for Q1 2027, pending stability data; positive pivotal bioequivalence results were reported for an undisclosed anticonvulsant candidate.

  • Strategy emphasizes approved generics, additional ANDAs, pipeline candidates, licensing and co-development; Nasdaq listing is targeted for March 2027, subject to shareholder elections and application steps.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Elite Pharmaceuticals earnings date

Logotype for Elite Pharmaceuticals Inc
Q3 202717 Feb, 2027
Elite Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Elite Pharmaceuticals earnings date

Logotype for Elite Pharmaceuticals Inc
Q3 202717 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Elite Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development, manufacture, and distribution of niche generic and oral controlled-release medications. The company primarily targets the opioid abuse-deterrent and extended-release segments of the pharmaceutical market, offering treatments across a variety of therapeutic areas. Elite Pharmaceuticals specializes in developing formulations that address controlled substance regulations and the potential for abuse. The company’s business model includes both the commercialization of its own products and contract manufacturing services for third-party pharmaceutical companies. The company is headquartered in Northvale, New Jersey, and its shares are listed on the OTCQB.